TheUrbanFarmer

The American people deserve the truth. FDA, do you remember Covaxin? The traditional whole-virion vaccine that you forced to jump through every bureaucratic hoop, while you were fast-tracking mRNA boosters based on trials conducted on just 8 mice? You urged the company to seek approval through a U.S. BLA trial, and they did—spending over $100 million on a massive Phase 3 trial that yielded top-line data showing broad protection against all variants of concern. Yet, despite this, you never approved an alternative traditional vaccine option after they successfully navigated your obstacle course. Why? Because just months after those results were published, you changed the rules to block any vaccine built on the original virus. This effectively killed the market for traditional vaccines based on the whole coronavirus. Meanwhile, you rolled out the next set of mRNA boosters, designed to mimic just a tiny piece of the spike protein on a virus that’s famously studied for its high mutation rates. It’s been four long years, and you still haven’t approved any competitor vaccines. The government collects royalties from mRNA sales, with companies like Moderna paying over $400 million in a single year. But those profits wouldn’t roll in from a traditional vaccine sale, would they? How has this financial entanglement influenced your decision-making during the pandemic? Your job is to serve the public—to prioritize science and protect the American people. But you’ve failed in that duty. Instead, you’ve used taxpayer dollars to accelerate only the development of “vaccines” that you own patents on, blocking all competitor vaccines for over four years. Do you really think the American people will trust that this next round of mRNA boosters will finally work, after six previous rounds failed to deliver? Your actions have severely damaged your credibility. Government entities should never receive kickbacks from the sales of drugs they’re responsible for approving. This is an egregious conflict of interest, and we’re living with the consequences. The amount of blood on your hands is staggering. Next-generation vaccines that have been proven to stop transmission are approved overseas, yet Americans have no choice but to take this mRNA snake oil. This is the biggest scam our country has ever seen. It’s time for real journalism to uncover the truth. There must be accountability, and the American people deserve to know who the main perpetrators are. Rest in peace to all those lost in this pandemic due to this corruption.

@IvandeaGreat 🤣

$OCGN People who have been in OCGN for 5 years

$ocgn channelchek.com/news-channel/o…

$ocgn just showed they have the new standard of care for GA, phase 3 starts this year, market dumps early retail panics, everyone worrying about results that point to the next standard of care… Next OCU410ST Pivotal 2/3 announces enrollment completion, another blockbuster clock starts, this one comes with a PRV on approval which will be worth around $200-$250 million. OCU400 rolling BLA starts, will target 99% of the RP market and Ocugen will transform from a pre revenue bio to a leader in gene therapy’s. You can choose to focus on the day to day noise, worry about the volatility and question what you own. Or you can focus on the facts, capitalize and enjoy knowing you own the next pharmaceutical giant before the rest of the world catches on. No 🧠’er 🍻 🐂

Today, CEO @drsmusunuri shares encouraging 12-month Phase 2 results for #OCU410 in GA, showing impact on lesion growth and visual function. A one-time gene therapy approach with potential to shift the landscape and address unmet needs.   Read more: bit.ly/4lLGXYV

Live Webcast Phase 2 ArMaDa trial on 3/24

It should be complete pretty soon, but they may not make anything public until both cohorts are ready. I’m starting to think they hold off now. I honestly didn’t expect the broad arm to dose anywhere near this fast given the rarity of some of these mutations, but clearly the word spread globally and people came from everywhere to get into this trial. Now the question is, if broad is only months behind RHO, do they really spend millions to file an RHO only label just to spend millions again expanding it shortly after? It’s a good problem to have, but the incentives shifted. To me the play now is, assuming confidence on broad data is high, get the BLA/CMC to be ready, then file the RHO module work while waiting for broad to gain the full label. Either way the companies story this year is stacked. OCU410 results likely retates this to new heights, BLA starts, OCU410st full enrollment, 30 million, partnerships, secured future. Just nothing but insane growth this year and for many years to come. 🍻

@NattaCop Hope to also hear bout OCU400 RHO arm as that should be complete and we should be compiling data

$ocgn quad witching, they do this every time and kill the calls. Big data comes out within the next two weeks. Gonna be a green Monday. 🍻

Why would one be? This is drugs not cow bells, a phase 2’s whole purpose is finding the optimal dosage. The medium dose looks like the sweet spot, while the high dose is still vastly superior than current standard of care. Ignore the noise, even from self proclaimed bio-analyst, many don’t even know the basics. 🍻

@NattaCop Are we worried about the inverse between the medium dose and high dose? Efficacy is overall good and 46 percent reduction but just curious? Apparently it’s not good?

$ocgn OCU410 analysis and US revenue projections. Most won’t realize how conservative this really is. 🍻

Just over a month since this post and I still think it’s a cheap price at $2.65. @Ocugen #Ocufam

@michaelrossow2 Me speculating Japan will be the next partnership

@NattaCop Partnership with Japan can't be found or is it just speculation?

$ocgn 🔮 Ocugen gets 5 days with over $2.5 VWAP, Ocugen gets $30 million, Ocugen announces a partnership like japan, stock steady moving 🚀, Ocugen announces another partnership, rolling BLA starts and much much more. Exciting times indeed. 🍻

@bob_aitken74 @PolarizingLit @tim_pscl Only to buy shares after selling calls if you like money.

@PolarizingLit @tim_pscl @NattaCop thoughts?

$ocgn ... holding calls for Jan 2027

Another Voice At The Table on.soundcloud.com/GbbVPzKhK9Ohtc…

@m56804962 VWAP above $2.5 for 5 out of the last 30 days. VWAP today was just over $2.5, today marks day 1 out of 5. 🍻

@NattaCop 2.48

$ocgn $2.5 means $30 million dollars and $30 million dollars = BLA, approval and future is secured. Road to big pharma. 🍻

@Kingscourt99 Just for 5 days out of the last 30

@NattaCop 5 days in a row, correct?

$ocgn Imagine seeing OCU410 results drop: One single subretinal injection. ONE. Not monthly/bi monthly eye shots for the rest of your life like Syfovre or Izervay. One shot and 12 months later patients saw 54% reduction in lesion growth and photoreceptor preservation at 60%. Twice the efficacy of Syfovre/Izervay… in half the time… with one shot instead of lifetime eye shots. Light. Fucking. Years. Ahead. Now imagine you’re the self proclaimed “bio analyst” Terry Chrisomalis @BioAnalysisCent who sees these nuclear results and immediately bangs out a @SeekingAlpha hit piece proving to the entire internet you know jack shit about trials, gene therapy, or the market. Gonna downgrade the stock because the high dose didn’t edge out the medium one? 🤣 You do know Phase 2s are literally designed to find the optimal dose, right? A real “bio analyst” would obviously know that… right Terry? 🤪 Seriously tho this is the single most legendary dog water take I’ve read in a decade of bios. You couldn’t have missed the mark more if you tried lmao. If you’re a retail investor getting wrecked out there, it’s probably because you’re swallowing “analysis” from morons like Terry on Seeking Alpha. These clowns don’t analyze a damn thing, they’re roll playing and vomiting their ignorance for ad revenue. You don’t need knowledge anymore. Just slap “bio analyst” in your bio and Seeking Alpha will hire you on the spot. Fake it till you make it, isn’t that right, Terry 🤡

@Kingscourt99 @MoreFlax Absolutely no concern, some fear headlines about a narrow vote counting dispute from a 2024 interpretation. Court is expediting certifying the correction to clarify. Literally is nothing. Well except a good buying opportunity 🤑

@MoreFlax @NattaCop What is your opinion on the news today and being down 12% ? Anything to be concerned?

$OCGN #OCUGEN 👇 👇 👇